EE201100023A - Ravimite kombinatsioon, mis sisaldab rasvhapet ja uridiin hendit, ja selle kasutamine - Google Patents

Ravimite kombinatsioon, mis sisaldab rasvhapet ja uridiin hendit, ja selle kasutamine

Info

Publication number
EE201100023A
EE201100023A EEP201100023A EEP201100023A EE201100023A EE 201100023 A EE201100023 A EE 201100023A EE P201100023 A EEP201100023 A EE P201100023A EE P201100023 A EEP201100023 A EE P201100023A EE 201100023 A EE201100023 A EE 201100023A
Authority
EE
Estonia
Prior art keywords
combination
fatty acid
products containing
medicinal products
containing fatty
Prior art date
Application number
EEP201100023A
Other languages
English (en)
Estonian (et)
Inventor
Susilo Rudy
Original Assignee
Trommsdorff Gmbh & Co. Kg Arzneimittel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trommsdorff Gmbh & Co. Kg Arzneimittel filed Critical Trommsdorff Gmbh & Co. Kg Arzneimittel
Priority claimed from EEP200300536A external-priority patent/EE05434B1/xx
Publication of EE201100023A publication Critical patent/EE201100023A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
EEP201100023A 2001-04-30 2002-04-29 Ravimite kombinatsioon, mis sisaldab rasvhapet ja uridiin hendit, ja selle kasutamine EE201100023A (et)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01110608 2001-04-30
US28809001P 2001-05-03 2001-05-03
EP01124879 2001-10-18
US33042901P 2001-10-22 2001-10-22
EEP200300536A EE05434B1 (et) 2001-04-30 2002-04-29 Farmatseutiliselt aktiivsed uridiiniestrid

Publications (1)

Publication Number Publication Date
EE201100023A true EE201100023A (et) 2011-08-15

Family

ID=32598659

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP201100023A EE201100023A (et) 2001-04-30 2002-04-29 Ravimite kombinatsioon, mis sisaldab rasvhapet ja uridiin hendit, ja selle kasutamine

Country Status (5)

Country Link
US (4) US7560442B2 (sr)
JP (1) JP4880190B2 (sr)
EA (1) EA200301204A1 (sr)
EE (1) EE201100023A (sr)
RS (2) RS51031B (sr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20050158258A1 (en) * 2004-01-21 2005-07-21 Mary Kay Inc. Methods and compositions for the treatment of skin changes associated with aging and environmental damage
US8084500B2 (en) * 2005-01-14 2011-12-27 Nutrition Therapeutics, Inc. Method of using catalpic acid to treat dyslipidemia
US7687544B2 (en) * 2005-01-14 2010-03-30 Nutrition Therapeutics, Inc. Method of using catalpic acid to treat type 2 diabetes and associated disorders
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
EP2012753A2 (en) * 2006-04-28 2009-01-14 Schering Corporation Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
WO2009097596A1 (en) * 2008-01-31 2009-08-06 Paul Griffin Compositions and methods for the treatment of chronic infections
US8329663B2 (en) * 2008-01-31 2012-12-11 Paul Griffin Compositions and methods for the treatment of chronic infections
CN102088965B (zh) * 2008-05-13 2013-05-08 根梅迪卡治疗公司 水杨酸盐(酯)缀合物在制备用于治疗代谢性病症的药物中的应用
US8950583B2 (en) * 2008-12-06 2015-02-10 Ermes Medical Company Limited Method to remove heavy metals from a mammal
JP2012520342A (ja) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
CN102421424A (zh) * 2009-03-16 2012-04-18 根梅迪卡治疗公司 用于治疗代谢性疾病的组合疗法
US8575218B2 (en) * 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
EP2483239A4 (en) * 2009-09-28 2014-09-03 Univ Kentucky Res Found THIOL-CONTAINING COMPOUNDS FOR REMOVING ELEMENTS FROM A CONTAMINATED ENVIRONMENT AND USE METHOD THEREFOR
US8426368B2 (en) * 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet
JP2012041283A (ja) * 2010-08-17 2012-03-01 Porien Project Kk 血管新生抑制剤
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
CN105612155A (zh) * 2012-05-10 2016-05-25 塞利克斯比奥私人有限公司 治疗局部疼痛的组合物和方法
KR102325668B1 (ko) * 2013-10-23 2021-11-12 켐진스 코포레이션 고체 표면에 생체분자의 강한 고정용 디티올란 기능화된 뉴클레오시드 아미디트 및 지지체
WO2016008603A1 (en) * 2014-07-16 2016-01-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Food intake, body weight and glucose metabolism regulation by modulation of p2y6 receptor signaling
EP3002010A1 (en) * 2014-09-30 2016-04-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Food intake, body weight and glucose metabolism regulation by modulation of P2Y6 receptor signaling
KR102354784B1 (ko) 2015-08-05 2022-01-25 메트로 인터내셔널 바이오테크 엘엘씨 니코틴아미드 모노뉴클레오티드 유도체 및 그 용도
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
WO2017155386A1 (en) * 2016-03-08 2017-09-14 N.V. Nutricia Method for treating brain atrophy
EP3558312A4 (en) 2016-12-21 2021-01-13 Newsouth Innovations Pty Limited METHODS FOR INCREASING VASCULAR DENSITY
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
US10618927B1 (en) * 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
BR112023024712A2 (pt) 2021-05-27 2024-02-15 Metro Int Biotech Llc Sólidos cristalinos de mononucleotídeo de ácido nicotínico e ésteres dos mesmos e métodos de fabricação e uso

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8319073D0 (en) * 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
DE3883374T2 (de) * 1987-10-28 1993-12-09 Pro Neuron Inc Acylatiertes uridin und cytidin und deren verwendungen.
US5736531A (en) * 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US6090839A (en) * 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents

Also Published As

Publication number Publication date
JP2004531543A (ja) 2004-10-14
RS51031B (sr) 2010-10-31
US7915234B2 (en) 2011-03-29
US7417034B2 (en) 2008-08-26
RS20100077A (sr) 2010-10-31
US20050065110A1 (en) 2005-03-24
US7396826B2 (en) 2008-07-08
JP4880190B2 (ja) 2012-02-22
EA200301204A1 (ru) 2004-04-29
YU76503A (sh) 2006-05-25
US7560442B2 (en) 2009-07-14
US20050043269A1 (en) 2005-02-24
US20040121979A1 (en) 2004-06-24
US20050043394A1 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
ATE296619T1 (de) Feste orale dosierungsform von simethicon
EP1539122A4 (en) PHARMACEUTICAL AQUEOUS 2,6-DIISOPROPYLPHENOL COMPOSITIONS
EE200200486A (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, uued derivaadid ja nende valmistamismeetodid
EE200300529A (et) Antraniilhappe amiidid, nende kasutamine ja farmatseutiline preparaat
FI20022129A7 (fi) Rasvahappokoostumus, sen valmistus ja käyttö
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
EE05183B1 (et) Asabitsklilised hendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
EE200300587A (et) Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine
ES2571219T8 (es) Formulación de compuestos de ácido borónico
ITMI20001732A0 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
DE60206889D1 (de) Pharmazeutische formulierung enthaltend bicalutamid
EE05020B1 (et) Glburiidi ravimkoostis
HUP0402616A3 (en) Biphenylmethyl-thiazolidinedones, biphenyl-propionic acid derivatives, their use as ppar-gamma activators and pharmaceutical and cosmetic compositions containing them
ATE353627T1 (de) Stabilisierte orale suspensionsformulierung
EE200300110A (et) Kaneelhappe asendatud guanidiidid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav ravim
IL157731A0 (en) Caboxylic acid derivatives and pharmaceutical compositions containing the same
EE04717B1 (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
EE200300488A (et) Lipiiditaset alandava toimega bifenüülkarboksamiidühend, meetod selle valmistamiseks ning seda sisaldav ravimkompositsioon
PL361518A1 (pl) Zastosowanie substancji oraz kompozycja farmaceutyczna
NO20042502L (no) Farmasoytisk formulering omfattende bicalutamid
EE200200252A (et) Antikehade kasutamine vaktsiinidena, antikehi sisaldavad farmatseutilised kompositsioonid, meetod antikehapreparaadi valmistamiseks ja meetod farmatseutilise kompositsiooni valmistamiseks
EE200200109A (et) Asendatud 3-fenüül-5-alkoksü-1,3,4-oksdiasool-2-oon, selle valmistamine ja kasutamine lipaasi inhibiitorina ning seda sisaldav ravim
EE200200637A (et) Torasemiidi uudne polümorf V, selle valmistamismeetod, kasutamine ja ravimvorm
EE200200480A (et) Memnopeptiidühend, selle valmistamine ja raviotstarbeline kasutamine ning seda sisaldav farmatseutiline kompositsioon